Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Biotechnology

Healthcare
$29.68 +1.50%

+$0.50 today

Market cap
$1.78B
Beta
0.59
P/E (TTM)
-4.7
EPS (TTM)
-$7.19
52W Low $22.24High $46.00

Volume 0.60M

Average 1.11M

AGIO Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Agios Pharmaceuticals, Inc.NASDAQ: AGIO

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 58.78M shares rose 2.3% year over year, in line with the +2.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +1.9% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +2.3% holds above the trailing-twelve-month pace of +2.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
58.78M+0.8% QoQ
Last fiscal yearDec 2025
57.97M+2.1% YoY
LTMMar 2026
58.3M+2.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.3%——
1 year+2.1%——
3-year CAGR+1.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
57.97M USD
Year-over-year change
+2.1%
4-year CAGR
-1.0%

Weighted Avg Shares vs competitors

How AGIO compares with its peers on the latest reported figures

  • AGIO's LTM Mar 2026 weighted avg shares of 58.3M shares is the 5th highest of the 7 companies compared; the peer median is 74.74M shares.
  • Its year-over-year change of +2.1% is the 6th highest of 7, against a peer median of +8.4%.
  • Over three fiscal years its annual growth of +1.9% compares with a peer median of +8.1%.
AGIO Competitors Peer median
Weighted Avg Shares for AGIO and competitors
Company Period LTM YoY 3-year CAGR
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026229.47M +10.2%+4.1%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202699.68M +6.6%+12.1%
PTCTPTC Therapeutics, Inc.LTM Jun 202681.93M +5.6%+3.5%
PHARPharming Group N.V.LTM Mar 202667.56M -5.0%-4.8%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 202658.3M +2.1%+1.9%
MIRMMirum Pharmaceuticals, Inc.LTM Jun 202657.35M +17.8%+14.0%
IRONDisc Medicine, Inc.LTM Sep 202637.84M +13.4%+223.8%
Peer median (excluding AGIO) 74.74M+8.4%+8.1%

Competitors are the stored peer set for AGIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue014.24M26.82M36.5M54.03M
Cost of Revenue18.78M1.7M9.5M4.17M11.52M
Gross Profit(18.78M)12.54M17.32M32.33M42.51M
Gross Margin—88.0%64.6%88.6%78.7%
Research & Development256.97M279.91M288.9M301.29M334.36M
Selling, General & Admin121.45M121.67M119.9M156.78M180.28M
Operating Expenses359.64M401.58M408.81M458.07M514.64M
Depreciation & Amortization18.78M8.56M6.62M5.65M5.18M
EBITDA(337.73M)(223.24M)(345.47M)723.62M(408.62M)
EBITDA Margin—-1567.7%-1287.9%1982.6%-756.3%
Operating Income(378.42M)(389.05M)(391.49M)(425.74M)(472.13M)
Operating Margin—-2732.1%-1459.5%-1166.5%-873.9%
Interest Income836K12.79M33.34M48.08M56.38M
Interest Expense00000
Other Income / Expenses21.91M157.25M39.4M1.14B58.34M
Income Before Tax(356.51M)(231.8M)(352.09M)717.97M(413.8M)
Pre-Tax Margin—-1627.8%-1312.6%1967.1%-765.9%
Income Tax Expense00044.24M(1.02M)
Net Income1.6B(231.8M)(352.09M)673.73M(412.78M)
Net Margin—-1627.8%-1312.6%1845.9%-764.0%
EPS (Basic)(6.36)(4.23)(6.33)11.86(7.12)
EPS (Diluted)(6.36)(4.23)(6.33)11.64(7.12)
Weighted Avg Shares60.45M54.79M55.65M56.81M57.97M
Weighted Avg Shares (Diluted)60.45M54.79M55.65M57.89M57.97M

Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Intrinsic Alpha fair value

Locked

Current Price

$29.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.